TimeLogic Overview

The TimeLogic DeCypher® solutions speed genomics research for customers within pharmaceutical, biotech, academic, and government research organizations worldwide.

Using extensive upfront genomic analysis on DeCypher, pharmaceutical companies mitigate downstream drug development risk and cost, which often exceeds $800M per drug candidate. Early use of extensive computing in the pharmaceutical R&D cycle sends only the best candidate compounds into the multi-year drug development pipeline.

The marketplace for accelerated bioinformatics computing is growing exponentially, as the underlying genetic databases double in size every six to nine months. Moore’s law stipulates that every 18 months, computing costs are reduced by half. Bioinformatics computational load, however, grows by about 8-fold—a net 4-fold constant-dollar cost increase after the benefit of Moore’s Law. Our DeCypher solution yields from 100x to 1,000x faster operation than conventional CPUs at 10x-100x better price-performance. In other words, DeCypher’s price-performance gain represents an instant jump of five to ten years on Moore’s Law driven improvements to conventional CPU-based servers and server farms.

DeCypher is an example of a Reconfigurable Computer—a relatively new computing solution, in which the hardware electronically adapts itself to optimally run different analyses. Direct execution in the Field Programmable Gate Array (“FPGA”) hardware, rather than as software on CPUs, results in raw speed and price-performance improvements over conventional computers, with dramatic savings in floor space, power, cooling, and total ownership costs when compared to small clusters or large server farms (hundreds of CPUs). One 3.5” tall rack-mount Dell 2550 server, accelerated with DeCypher, is the speed equivalent of 50 to over 1,000 CPUs, depending on the bioinformatic algorithm and sensitivity settings.

TimeLogic is owned by Active Motif, Inc. with headquarters in Carlsbad, CA.